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Introduction
The treatment options for terminal heart failure due to myocardial 
infarction or cardiomyopathy are limited [1]. However, few patients are 
eligible or able to receive these treatments, although there are last-resort 
options, including insertion of a ventricular assist device and a heart 
transplant. Under these conditions, recent clinical studies [2-4] and 
animal experiments [5,6] have demonstrated the positive effects of stem 
cell transplantation on ischemic heart disease. Several methods have 
been proposed for transplanting stem cells into the heart, including 
transvenous infusion, interstitial retrograde coronary venous delivery, 
intracoronary arterial infusion, surgical transepicardial infusion using 
a cell sheet and transendocardial injection using a catheter [7-10]. 
Although clinical reports have shown that the left ventricular ejection 
fraction improved following transvenous infusion and intracoronary 
arterial infusion [11-14], the injected cells tend to be more heavily 
distributed over the lungs and only a few cells ultimately engraft into 
the heart in comparison with intramyocardial infusion [9,10]. In 
addition, surgical infusion is a rather invasive procedure, and recurrent 
operations are risky and challenging [9]. 
Endocardial infusion, which enables more precise selection of a 
target area, can retain more of the original injected cells than possible 
with intracoronary infusion [9]. Although there are currently a few 
devices available for the intramyocardial delivery of cells [14-18], there 
are several aspects that require improvement. A few endomyocardial 
cell infusion devices have already been used in animal experiments 
and clinical trials [2,5,8,16-18]. For example, the Myostar™ catheter [2] 
requires an 8-Fr guiding catheter and does not have a mechanism for 
precise adjustment of the length and angle of the needle tip. To improve 
upon these current devices, we developed a simple and versatile 
catheter for transendocardial cell infusion, and aimed to investigate the 
safety and operability of our device by infusing adipose tissue-derived 
mesenchymal stem cells (MSCs) in swine hearts.
Materials and Methods
Animals
Female domestic swine (mean body weight 20.0 kg) were used for 
the animal experiments. The animal study was approved by the Animal 
Care and Use Committee of Kanazawa University, and the experiments 
were conducted in accordance with the “Basic Guidelines for the 
Conduct of Animal Experiments” published by the Ministry of Health, 
Labor and Welfare of Japan.
Device design 
Our cell infusion device consists of an electrode-guided bidirectional 
catheter with a platinum tip and a long inner needle. The length of the 
catheter is 75 cm, with a 25 cm flexible tip and a 50 cm rigid root. The 
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Abstract
Background: Endocardial infusion is a minimally invasive procedure for cell delivery with good selectivity to 
the target region. However, certain limitations to current devices could affect the precision of the procedure and the 
therapeutic outcome. Therefore, we developed an enhanced device for transendocardial cell infusion.
Methods and Results: Our device is based on an electrode-guided transendocardial bidirectional 75 cm long 
catheter and 0.5 mm diameter inner needle. The key advantages of our device are the slender catheter diameter 
(7 Fr), consistent needle tip length, regulation of the catheter angle and independence between the needle and 
catheter. Mesenchymal stem cells (MSCs) were obtained from the inguinal adipose tissue of six healthy swine 
and propagated through 2-3 passages. Using the catheter, pre-labeled MSCs were infused autogenously into the 
swine hearts. The MSCs-infused myocardial regions were harvested on the infusion day (day 0) or 2 days later, 
and histological analysis was performed. The MSCs were successfully infused into all six swine myocardia and 
distributed along the hole made by the needle. The spread area of MSCs was larger at 2 days after infusion than at 
day 0 (1.38 ± 0.26 vs. 0.51 ± 0.17 mm2/infusion, p=0.013). No complications occurred during the procedure, such as 
cardiac tamponade or arrhythmia.
Conclusion: These results demonstrate that our enhanced device could be useful for delivering cells into the 
myocardium.
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outer diameter of the catheter is 7 Fr. Five electrodes can be placed along 
the catheter at every 2 mm from the tip, although these functions were 
not used in the present study. The needle lumen is located in the center 
of the catheter. The inner needle is 0.5 mm in diameter (Figure 1).
The root of the needle contains a marked scale, which enables 
determining the position of the tip of the needle. In addition, a scale 
of 0-3 is labeled on the catheter grip that corresponds to the catheter 
angle: when the scale of the grip is +3, +2, +1 or 0, the degree of 
the catheter is 0°, 30°, 60° or 90°, respectively. In general, a needle 
protrudes more when the catheter is bent than when operated in a 
straight state. However, in our device, the extent of protrusion of 
the needle could be maintained at a constant length by matching the 
scale of the needle to the scales of the grip increasing by +1 (Figures 
2A-2L).
Cell preparation
After being anaesthetized with ketamine hydrochloride (20 mg/
kg intramuscularly; Daiichi Sankyo Propharma, Tokyo, Japan), the 
swine were maintained on general anesthesia with 2% sevoflurane 
(Inhalation; Mylan, Canonsburg, PA, USA) and oxygen. Adipose 
tissues were harvested from both sides of the inguinal region of the 
six swine. Harvested adipose tissues were minced with scissors and 
washed with Dulbecco’s modified Eagle’s medium (DMEM; Sigma-
Aldrich, St. Louis, MO, USA). After incubation with 0.1% collagenase 
type 1 (Worthington Biochemical Corporation, Lakewood, NJ, USA) 
at 37°C for 60 min, MSCs were separated by centrifugation at 400 g for 
10 min. MSCs were cultured in DMEM containing 15% fetal bovine 
serum (FBS; Invitrogen, Carlsbad, CA, USA) and 100 U/mL penicillin 
and 100 μg/mL streptomycin (P/S; Invitrogen). A small number of cells 
developed into visible symmetric colonies by days 5-7. Non-adherent 
hematopoietic cells were removed, and the medium was replaced. The 
adherent, spindle-shaped MSCs were expanded to passage 2-3 after the 
cells were first plated.
Fluorescent labeling
After 2-3 passages, the cultured cells were labeled using the PKH26 
Red Fluorescent Cell Linker Kit (Sigma-Aldrich) according to the 
manufacturer protocol. In brief, after washing with serum-free medium, 
the cells were treated with 4 mL/dish TrypLE (ThermoFisher Scientific, 
Waltham, MA, USA) and incubated at 37°C until the cells came off the 
dish. The cell suspension was mixed with DMEM containing 15% FBS 
and P/S and centrifuged. The supernatant was aspirated and suspended 
with Diulent C (Sigma-Aldrich). PKH26 (4 μL) was then added to the 
cell suspension mixed with 1 mL Diulent C. After incubation of the cell 
and dye suspension at 37°C for 5 min, FBS was added to stop the staining. 
The cells were centrifuged and washed several times. Before infusion, we 
confirmed that the cells had been successfully labeled with PKH using a 
fluorescent microscope (BZ-9000, KEYENCE, Osaka, Japan).
Preliminary experiment
As a preliminary experiment to validate the functionality of the 
device, we infused 0.4% trypan blue solution (Wako Pure Chemical 
Industries, Osaka, Japan) into the extracted swine heart and observed 
the expansion of the dye. The procedure to extract swine hearts and to 
infuse in vivo was described later.
Cell delivery
The anesthesia status was carefully monitored throughout the 
experimental procedure to maintain appropriate sedation. The 
electrocardiogram and heart rate were continuously monitored by a 
polygraph recording system (OptiPlex755, Nihon-Kohden, Tokyo, 
Japan) throughout the procedure.
Arterial access was obtained via the left carotid artery with a cut-
down technique and a 7-Fr vascular sheath was used to cannulate the 
artery. The cell infusion device was inserted through the sheath into the 
left ventricle. In the case that the tip of the device made contact with an 
obstacle in the left ventricle, an infusion needle was inserted through 
the lumen of the device. Approximately 5.0 × 106 MSCs per point were 
infused at 2-9 points in the apex of the left ventricle. 
Histological analysis
Three of the swine were anesthetized with ketamine hydrochloride 
and 2% sevoflurane and sacrificed with infusion of 20 mEq potassium 
chloride solution (Terumo Corporation, Tokyo, Japan) in the left 
atrium on the day of infusion (day 0) and the other three swine were 
sacrificed two days after infusion (day 2). The myocardium tissues of 
the cell infusion regions were harvested as blocks and fixed with 4% 
formaldehyde (Wako Pure Chemical Industries) for more than 24 h 
and embedded with 10%, 20% and 30% sucrose solutions (Wako Pure 
Chemical Industries). Cryosections were prepared using a cryostat 
(Leica CM1950, Leica Biosystems, Nussloch, Germany). By the 
observation with microscopy (KEYENCE), we measured the area in 
acknowledgment of PKH-labeled MSCs per slice. 
Safety evaluation 
The safety of the technique was evaluated according to the mortality, 
fatal arrhythmia during the procedure, bloody pericardial fluid, and 
damage to the cardiac structures (e.g. aortic and mitral valve structures, 
coronary and great vessels) caused by the device [19].
Figure 1: Design and appearance of the device. Our device consists of an electrode-guided bidirectional catheter with a platinum tip and long core needle. There 
is a 25 cm flexible catheter tip and a 50 cm rigid root; the outer diameter of the catheter is 7 Fr. There is a grip at the root of the device to adjust the angle. The core 
needle is 0.5 mm in diameter.
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Statistical analysis
The cell spread area was traced and measured under microscopy. 
Data are expressed as mean ± standard error of the mean. Comparison 
of the cell spread area was conducted with Welch’s t-test. Differences 
were considered statistically significant at p<0.05.
Results
Dye injection
When the needle was stabbed 3 mm into the swine myocardium, 
the trypan blue solution overflowed from the side of the needle with an 
injection amount greater than 0.4 mL. Therefore, we decided to infuse 
0.3 mL of the cell suspension, which corresponds to injection of 5 × 106 
MSCs per point.
For both the in vitro and in vivo preliminary tests, the dye spread 
radially along the epicardium side and endocardium side (Figure 3). 
The in vitro results suggested that the needle had been inserted at 
approximately the halfway point into the myocardium. No pericardial 
effusion of the dye was detected in the in vivo model. 
MSC characteristics
After 2 weeks of culture, spindle-like plastic-adherent cells 
increased in number, indicating the typical characteristics of MSCs 
(Figure 4A) [20,21]. Before cell infusion, we could observe that MSCs 
were labelled in PKH with microscopy (Figure 4B).
Observation of the harvested endocardium side of the myocardium 
showed clearly visible needle holes. Cryosections were successfully 
made of the myocardium regions containing the needle holes. PKH-
labeled MSCs were clearly visible in all cryosections from samples 
harvested on day 0 and day 2 after infusion (Figure 5). 
Figure 2: Length maintenance of the needle from the tip. (A–C) When the catheter is kept straight, the length of the tip of needle can be maintained at 3 mm by 
keeping the proximal marker at the entrance of the catheter. (D–L) When adjusting the angle of the catheter from 30° to 90°, the length of the needle tip can be kept 
to be 3 mm by pulling back the needle according to markers.
Figure 3: In vitro and in vivo preliminary experiments. A 0.4% trypan blue solution was poured into the myocardium using the device. In vitro injection the dye 
appeared on both the (A) endocardium and (B) epicardium sides. (C) Transverse section evaluation showed that the dye was distributed in a fan form along the hole 
made by the needle. When the length of the needle was 3 mm, the needle was inserted about halfway into the myocardium. In vivo infusion, the dye was observed 
in both the (D) endocardium and (E) epicardium sides.
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Most of the MSCs were engrafted along an intramyocardial needle 
hole. However, some of the MSCs infiltrated into the myocardium 
from the needle hole. Importantly, the spread area of MSCs determined 
by planimetry on day 2 was (1.38 ± 0.26 mm2/infusion) greater than 
that on day 0 (0.51 ± 0.17 mm2/infusion, p=0.013). This suggests that 
using the present device delivered MSCs could retain to exist in the 
myocardium at least for 48 h after injection in vivo. 
Safety of the protocol
The average number of infusion points was 4.5 (5.0 × 106 MSCs/
point). There were no deaths resulting from the infusion of MSCs. In 
addition, no case of fatal arrhythmia was observed in the six swine 
at the time of cell infusion. Bloody pericardial effusion, suggesting 
penetration of the needle, was not detected at the time of harvest.
Discussion
In this study, we demonstrate that our new device can be effectively 
used for cell injection in the swine myocardium. There are four unique 
aspects to this device. The first is the slender catheter diameter; most 
existing devices require an 8-Fr sheath, and our device can insert through 
a 7-Fr sheath [14]. Second, this device enables stability in the length of 
the needle tip, regardless of the catheter angle. Third, the catheter angle 
itself can be precisely controlled by regulating the grip position. Finally, 
the device is not an integrated unit, and this independence between the 
catheter and the needle allows for simply replacing the needle rather 
than requiring an entirely new device in the case that a needle hole 
occludes with the cell solution or myocardium. Thus, our device can 
accurately adjust the projection of a needle on its tip, and the angle of 
the catheter was precisely adjustable. In addition, our device could be 
used in electromechanical mapping with the CARTO® system (Biosense 
Webster), which is commonly used in catheter ablation.
Recently, the beneficial effects of cell sheet-based myocardial 
regeneration therapy have been reported [22,23]. However, this is a 
highly invasive procedure. Although transendocardial cell infusion 
Figure 4: Isolated adipose tissue-derived mesenchymal stem cells (MSCs). (A) Spindle-like cells at 2 weeks after seeding. (B) Before intramyocardial delivery, the 
MSCs were labeled with PKH (red). Nuclei were stained with DAPI (blue).
Figure 5: Overlay of the phase difference and fluorescence microscopy images on day 2. Note that most of the PKH-labeled MSCs were retained to stay along 
the hole of the needle in the myocardium.
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is associated with a low level of cell engraftment, some methods have 
been proposed to increase the engraftment ratio of the transplanted cells 
[24-27]. MSCs are thought to be particularly effective for regeneration 
therapy owing to their paracrine effect even when the cell survival rate is 
low [28-30], because MSCs secrete various vascularization factors such 
as vascular endothelial growth factor and hepatocyte growth factor [31]. 
In addition, various other agents besides cells have been infused using 
endocardium infusion devices, such as proteins or genes [32,33].
One of the disadvantages of the needle injection for cell delivery 
seemed to be unstable distribution of the injected materials, although 
some studies demonstrated that approximately 10% of the infused 
MSCs remained in the heart [9] and the infused cells could survive for 
approximately 6 weeks [26]. It was quite interesting that the area of 
MSCs after infusion was even greater on day 2 after infusion than that 
on day 0. One might speculate that the infused MSCs kept spreading at 
least during these periods.
There remain several limitations of the present device that should 
be explored prior to clinical assessment. First, we infused the MSCs 
into healthy swine and therefore did not examine the effectiveness 
of the procedure and the optimal number of cells to infuse per point 
for treating a diseased heart. Second, we did not examine the ratio of 
retained cells and the long-term survival of the infused cells. To resolve 
these, further experiments with disease heart models for long-term 
observation are warranted to determine the utility of the present device.
Conclusion
We manufactured an enhanced device for cell delivery to the 
myocardium. Adipose tissue-derived MSCs were clearly detected in 
the swine myocardium on day 0 and day 2 after infusion. Our device 
overcomes some technical limitations of current devices, and shows 
promise for clinical applications in cell-based therapy for heart disease.
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